Evidence map›Paper›PMID 32606031›Full record

ArticlemSystems2020

Interindividual Variation in Dietary Carbohydrate Metabolism by Gut Bacteria Revealed with Droplet Microfluidic Culture.

Max M Villa, Rachael J Bloom, Justin D Silverman, Heather K Durand, Sharon Jiang, Anchi Wu, Eric P Dallow, Shuqiang Huang, Lingchong You, Lawrence A David

Abstract read
In one paragraph

Article in mSystems, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. A Guide to Biodetection in Droplets.Analytical chemistry · 2024
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Gut microbiota in colorectal cancer development and therapy.Nature reviews. Clinical oncology · 2023
    Review
  20. [Application of Droplet-Based Microfluidics in Microbial Research].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Max M Villa *Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0002-8275-0133
Rachael J Bloom *Center for Genomic and Computational Biology, Duke University, Durham, North Carolina, USA.
Justin D SilvermanCollege of Information Science and Technology, Penn State University, University Park, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-3063-2098
Heather K DurandDepartment of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA.
Sharon JiangDepartment of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA.
Anchi WuDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, USA.
Eric P DallowDepartment of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA.
Shuqiang HuangShenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, People's Republic of China.
Lingchong YouCenter for Genomic and Computational Biology, Duke University, Durham, North Carolina, USA.
Lawrence A DavidDepartment of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA lawrence.david@duke.edu.ORCID https://orcid.org/0000-0002-3570-4767

Funding

UNIV OF NORTH CAROLINA CLINICAL NUTRITION RESEARCH UNITP30DK056350 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SUSAN M. SMITH · 1999 to 2026
$31.6M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2M
PILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1985 to 2026
$30.5M
Personalizing prebiotic therapies that target human gut microbiotaR01DK116187 · NIDDK · DUKE UNIVERSITY · PI Lawrence Anthony David · 2018 to 2026
$3.7M
NIDDK NIH HHS P30 DK034987NIDDK NIH HHS P30 DK056350NIDDK NIH HHS R01 DK116187NIGMS NIH HHS T32 GM007171
6 · The paper itself

Abstract

Culture and screening of gut bacteria enable testing of microbial function and therapeutic potential. However, the diversity of human gut microbial communities (microbiota) impedes comprehensive experimental studies of individual bacterial taxa. Here, we combine advances in droplet microfluidics and high-throughput DNA sequencing to develop a platform for separating and assaying growth of microbiota members in picoliter droplets (MicDrop). MicDrop enabled us to cultivate 2.8 times more bacterial taxa than typical batch culture methods. We then used MicDrop to test whether individuals possess similar abundances of carbohydrate-degrading gut bacteria, using an approach which had previously not been possible due to throughput limitations of traditional bacterial culture techniques. Single MicDrop experiments allowed us to characterize carbohydrate utilization among dozens of gut bacterial taxa from distinct human stool samples. Our aggregate data across nine healthy stool donors revealed that all of the individuals harbored gut bacterial species capable of degrading common dietary polysaccharides. However, the levels of richness and abundance of polysaccharide-degrading species relative to monosaccharide-consuming taxa differed by up to 2.6-fold and 24.7-fold, respectively. Additionally, our unique dataset suggested that gut bacterial taxa may be broadly categorized by whether they can grow on single or multiple polysaccharides, and we found that this lifestyle trait is correlated with how broadly bacterial taxa can be found across individuals. This demonstration shows that it is feasible to measure the function of hundreds of bacterial taxa across multiple fecal samples from different people, which should in turn enable future efforts to design microbiota-directed therapies and yield new insights into microbiota ecology and evolution.

Indexed as

bacteriadietdropletfibergutmicrobiomemicrofluidicspolysaccharidesprebiotics

Identifiers

PMID32606031
PMCPMC7329328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.